Literature DB >> 8760010

Mutations associated with carcinomas arising from pleomorphic adenomas of the salivary glands.

Y Yamamoto1, Y Kishimoto, A K Virmani, A Smith, F Vuitch, J Albores-Saavedra, A F Gazdar.   

Abstract

Pleomorphic adenoma (PA) is the most common benign tumor of salivary glands. Carcinomas in pleomorphic adenomas (CPAs) may arise by malignant transformation of the epithelial components of PAs. Occasionally, transitional zones containing cells with histological features intermediate between those of the benign PA and carcinomatous components of CPA are identified. After careful microdissection of archival microslides, the authors studied 12 cases of CPAs and their attendant adenomatous and transitional areas for mutations in the p53, RB, and K-ras genes, and at chromosomal loci 5q and 9p. The authors failed to find mutations in the K-ras gene or 9p locus. A relatively high rate of mutations (loss of heterozygosity [LOH] and microsatellite alterations) at the p53 gene were detected in CPAs (58%), and at somewhat lower frequencies at the RB gene (33%) and chromosomal location 5q (17%). Mutational frequency in the associated transitional and adenomatous areas were slightly lower than in the corresponding CPAs. No mutations were detected in adenomatous or transitional areas unless they also were present in the corresponding CPAs. Mutations of these three genes were absent in four cases of CPA, and in seven PAs without malignant change. These findings indicate that most CPAs arise from adenomas as the result of mutations in the three genes, especially p53. In addition, other, as yet unidentified genes may also be involved both in the development of PA and in its malignant progression to CPA. Mutational analysis of PAs may provide information of prognostic importance.

Entities:  

Mesh:

Year:  1996        PMID: 8760010     DOI: 10.1016/s0046-8177(96)90449-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  11 in total

1.  HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.

Authors:  I E Krop; D Sgroi; D A Porter; K L Lunetta; R LeVangie; P Seth; C M Kaelin; E Rhei; M Bosenberg; S Schnitt; J R Marks; Z Pagon; D Belina; J Razumovic; K Polyak
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 2.  [Diagnosis and prognosis of salivary gland tumors. An interpretation of new revised WHO classification].

Authors:  G Seifert
Journal:  Mund Kiefer Gesichtschir       Date:  1997-09

3.  Loss of heterozygosity occurs predominantly, but not exclusively, in the epithelial compartment of pleomorphic adenoma.

Authors:  Micaela Poetsch; Anett Zimmermann; Eduard Wolf; Britta Kleist
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

4.  A case of myoepithelial carcinoma displaying biallelic inactivation of the tumour suppressor gene APC in a patient with familial adenomatous polyposis.

Authors:  J Young; M Barker; T Robertson; S Nasioulas; A Tannenberg; R L Buttenshaw; N Knight; J R Jass; B A Leggett
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

5.  Myoepithelial carcinoma (malignant myoepithelioma) of the parotid gland arising in a pleomorphic adenoma.

Authors:  W G McCluggage; W J Primrose; P G Toner
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

Review 6.  Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved.

Authors:  Markus Stenner; J Peter Klussmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-04       Impact factor: 2.503

7.  Satellite tumors surrounding primary pleomorphic adenomas of the parotid gland.

Authors:  Yorihisa Orita; Kazuo Hamaya; Kentaroh Miki; Akiko Sugaya; Misato Hirai; Kiyoko Nakai; Sohichiroh Nose; Tadashi Yoshino
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-11-07       Impact factor: 2.503

8.  Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas.

Authors:  T Schneider; A Strehl; C Linz; R Brands; S Hartmann; F Beckford; A Rosenwald; A C Kübler; U D A Müller-Richter
Journal:  Clin Oral Investig       Date:  2015-08-06       Impact factor: 3.573

9.  Assessment of TP53 mutations in benign and malignant salivary gland neoplasms.

Authors:  Carolina Cavaliéri Gomes; Marina Gonçalves Diniz; Lissur Azevedo Orsine; Alessandra Pires Duarte; Thiago Fonseca-Silva; Brendan I Conn; Luiz De Marco; Cláudia Maria Pereira; Ricardo Santiago Gomez
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

10.  Immunohistochemical Expression of p53 in Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma.

Authors:  Bassel Tarakji; Omar Kujan; Mohammad Z Nassani
Journal:  J Cancer Epidemiol       Date:  2010-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.